https://labiotech.eu/features/pd-1-pd-l1-checkpoint-inhibitors/...

https://labiotech.eu/features/pd-1-pd-l1-checkpoint-inhibitors/ features a recently-updated article that questions whether Check Point Inhibitors are living up to the hype.  It seems not.

“Biotech and pharma now seem convinced that the solution lies in combining checkpoint inhibitors with other cancer treatments. Everyone’s giving it a try, hoping that their own therapies will improve the safety and efficacy of the successful PD-1 and PD-L1 inhibitors.  But many of them might just be jumping in blindly. “Rational combination of clinical strategies should be based on strong biological principles, and we have a lot of clinical trials being done now that may not have that rationale,” Masoud Tavazoie, CEO of the immuno-oncology biotech Rgenix, told me. “Over the next two to three years we’re gonna start to see the real winners. And the losers, which are likely based on poor combinations.

In my opinion, investors should be considering the potential investment value of Veyonda® :

1. If it makes one of the huge-selling immuno-oncology drugs work more effectively in more patients, in a broader range of cancer types and with greatly reduced side-effects? (e.g. in the proposed IONIC trial listed in the latest Corporate Presentation, which will probably use Veyonda + immune-oncology drug + radiotherapy)

2. Investors should note that so far, the immuno-oncology drugs are not showing promise in two of the most common cancer types; prostate and breast cancer. We know that Veyonda has been shown in its clinical trials to have an anti-cancer effect in both these cancers.

3. Current pharmaceutical trials are predominantly focusing on immuno-oncology drugs with other chemotherapies, although there are some I-O and radiotherapy trials underway. We know that Veyonda can be used with both chemotherapy AND radiotherapy. This versatility has enormous potential value in the pharmaceutical oncology industry.